Close Menu
Nabka News
  • Home
  • News
  • Business
  • China
  • India
  • Pakistan
  • Political
  • Tech
  • Trend
  • USA
  • Sports

Subscribe to Updates

Subscribe to our newsletter and never miss our latest news

Subscribe my Newsletter for New Posts & tips Let's stay updated!

What's Hot

Flutter (FLUT) Q2 2025 earnings report

August 7, 2025

Khawaja Asif denies resignation, labels viral tweet fake

August 7, 2025

OpenAI launches new GPT-5 model for all ChatGPT users

August 7, 2025
Facebook X (Twitter) Instagram
  • Home
  • About NabkaNews
  • Advertise with NabkaNews
  • DMCA Policy
  • Privacy Policy
  • Terms of Use
  • Contact us
Facebook X (Twitter) Instagram Pinterest Vimeo
Nabka News
  • Home
  • News
  • Business
  • China
  • India
  • Pakistan
  • Political
  • Tech
  • Trend
  • USA
  • Sports
Nabka News
Home » Eli Lilly (LLY) Q2 2025 earnings report
Business

Eli Lilly (LLY) Q2 2025 earnings report

i2wtcBy i2wtcAugust 7, 2025No Comments3 Mins Read
Share Facebook Twitter Pinterest LinkedIn Tumblr Email WhatsApp Copy Link
Follow Us
Google News Flipboard Threads
Share
Facebook Twitter LinkedIn Pinterest Email Copy Link


Eli Lilly on Thursday hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster weight loss and diabetes drugs.

The company raised its fiscal 2025 sales guidance to $60 billion to $62 billion, from a previous outlook of $58 billion to $61 billion on underlying strength across its business. The pharmaceutical giant also expects its adjusted fiscal 2025 earnings to come in between $21.75 and $23, up from previous guidance of $20.78 to $22.28 per share. 

Eli Lilly said the guidance reflects President Donald Trump’s existing tariffs as of Aug. 7, but does not include his planned levies on pharmaceuticals imported into the U.S.

Also on Thursday, Eli Lilly released long-awaited late-stage trial data on its experimental obesity pill, orforglipron, the highest dose of which helped patients lose more than 12% of their body weight. That came under Wall Street’s expectations, sending the company’s shares down as much as 12% in premarket trading Thursday.

“I feel good about the value of the company. Investors have to decide what they think,” Eli Lilly CEO David Ricks told CNBC’s “Squawk Box.” “But Lilly is rolling, and you look at the beat and raise, strong growth on the back half, we’re excited about the future for our company and for patients who need our products.”

The company’s diabetes treatment Mounjaro topped expectations for the second quarter, raking in almost $5.2 billion in revenue. That’s up 68% from the same period a year ago.

Eli Lilly’s weight loss drug Zepbound also beat estimates, booking $3.38 billion in sales for the quarter, up a whopping 172% from the year-earlier period. 

Analysts had expected Mounjaro and Zepbound to generate $4.49 billion and $3.06 billion in sales, respectively, according to estimates from StreetAccount.

“Tirzepatide, which is Mounjaro and Zepbound, will likely become the bestselling drug in the industry in its third year in the market,” Ricks told CNBC. “And we’ve got a lot more coming in the pipeline.”

Here’s what Eli Lilly reported for the second quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG: 

Earnings per share: $6.31 adjusted vs. $5.57 expectedRevenue: $15.56 billion vs. $14.71 billion expected

The company posted second-quarter revenue of $15.56 billion, up 38% from the same period a year ago. 

Sales in the U.S. jumped 38% to $10.81 billion. Eli Lilly said that was driven by a 46% increase in volume — or the number of prescriptions or units sold — for its products, primarily for Mounjaro and Zepbound. That was partially offset by lower realized prices of the drugs, the company said.

The pharmaceutical giant booked net income of $5.66 billion, or $6.29 per share, for the second quarter. That compares with net income of $2.97 billion, or $3.28 per share, a year earlier. 

Excluding one-time items associated with the value of intangible assets and other adjustments, Eli Lilly posted earnings of $6.31 per share for the second quarter.

The results also come as Eli Lilly and other drugmakers brace for levies on pharmaceuticals imported into the U.S. and face Trump’s calls to lower drug prices in the country.

The president sent letters to Eli Lilly and other companies last week calling on them take steps to lower drug prices by Sept. 29. The move came after Trump in May signed an executive order reviving a controversial plan, the “most favored nation” policy, that aims to slash drug costs by tying the prices of some medicines in the U.S. to the significantly lower ones abroad.



Source link

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email WhatsApp Copy Link
i2wtc
  • Website

Related Posts

Business

Flutter (FLUT) Q2 2025 earnings report

August 7, 2025
Business

After 15 years, the Giving Pledge yields mixed results

August 7, 2025
Business

Warner Bros. Discovery film studios lift second-quarter results

August 7, 2025
Business

Craveworthy Brands becomes managing partner of Gregorys Coffee

August 7, 2025
Business

American adds Budapest, Prague and Buenos Aires flights for 2026

August 7, 2025
Business

Eli Lilly obesity pill orforglipron led to 12% weight loss

August 7, 2025
Add A Comment
Leave A Reply Cancel Reply

Top Posts

Flutter (FLUT) Q2 2025 earnings report

August 7, 2025

House Republicans unveil aid bill for Israel, Ukraine ahead of weekend House vote

April 17, 2024

Prime Minister Johnson presses forward with Ukraine aid bill despite pressure from hardliners

April 17, 2024

Justin Verlander makes season debut against Nationals

April 17, 2024
Don't Miss

Trump says China’s Xi ‘hard to make a deal with’ amid trade dispute | Donald Trump News

By i2wtcJune 4, 20250

Growing strains in US-China relations over implementation of agreement to roll back tariffs and trade…

Donald Trump’s 50% steel and aluminium tariffs take effect | Business and Economy News

June 4, 2025

The Take: Why is Trump cracking down on Chinese students? | Education News

June 4, 2025

Chinese couple charged with smuggling toxic fungus into US | Science and Technology News

June 4, 2025

Subscribe to Updates

Subscribe to our newsletter and never miss our latest news

Subscribe my Newsletter for New Posts & tips Let's stay updated!

About Us
About Us

Welcome to NabkaNews, your go-to source for the latest updates and insights on technology, business, and news from around the world, with a focus on the USA, Pakistan, and India.

At NabkaNews, we understand the importance of staying informed in today’s fast-paced world. Our mission is to provide you with accurate, relevant, and engaging content that keeps you up-to-date with the latest developments in technology, business trends, and news events.

Facebook X (Twitter) Pinterest YouTube WhatsApp
Our Picks

Flutter (FLUT) Q2 2025 earnings report

August 7, 2025

Khawaja Asif denies resignation, labels viral tweet fake

August 7, 2025

OpenAI launches new GPT-5 model for all ChatGPT users

August 7, 2025
Most Popular

China, Belarusian militaries conduct joint anti-terrorism drills

July 7, 2024

Australia accuses China-backed hackers of infiltrating government networks

July 9, 2024

Cooking oil scandal may lead China to tighten food safety policies, observers say

July 10, 2024
© 2025 nabkanews. Designed by nabkanews.
  • Home
  • About NabkaNews
  • Advertise with NabkaNews
  • DMCA Policy
  • Privacy Policy
  • Terms of Use
  • Contact us

Type above and press Enter to search. Press Esc to cancel.